CN101580548B - 抑制肿瘤生长的融合肽及其在制备抗肿瘤药物中的用途 - Google Patents
抑制肿瘤生长的融合肽及其在制备抗肿瘤药物中的用途 Download PDFInfo
- Publication number
- CN101580548B CN101580548B CN 200810097542 CN200810097542A CN101580548B CN 101580548 B CN101580548 B CN 101580548B CN 200810097542 CN200810097542 CN 200810097542 CN 200810097542 A CN200810097542 A CN 200810097542A CN 101580548 B CN101580548 B CN 101580548B
- Authority
- CN
- China
- Prior art keywords
- cell
- peptide
- sequence
- tumor
- tat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 112
- 230000004614 tumor growth Effects 0.000 title claims abstract description 15
- 239000003814 drug Substances 0.000 title abstract description 27
- 230000000259 anti-tumor effect Effects 0.000 title abstract description 12
- 230000002401 inhibitory effect Effects 0.000 title abstract description 11
- 230000004927 fusion Effects 0.000 title abstract description 9
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 32
- 230000026683 transduction Effects 0.000 claims abstract description 31
- 238000010361 transduction Methods 0.000 claims abstract description 31
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 23
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 20
- 230000014509 gene expression Effects 0.000 claims abstract description 18
- 239000003446 ligand Substances 0.000 claims abstract description 11
- 108010001857 Cell Surface Receptors Proteins 0.000 claims abstract description 8
- 102000006240 membrane receptors Human genes 0.000 claims abstract 2
- 206010028980 Neoplasm Diseases 0.000 claims description 40
- 230000000799 fusogenic effect Effects 0.000 claims description 32
- 206010009944 Colon cancer Diseases 0.000 claims description 17
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 9
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 229940041181 antineoplastic drug Drugs 0.000 claims description 8
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 8
- 230000005764 inhibitory process Effects 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 201000000498 stomach carcinoma Diseases 0.000 claims description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 67
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 28
- 230000008685 targeting Effects 0.000 abstract description 7
- 230000008105 immune reaction Effects 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 description 46
- 101710138522 Bcl-2-binding component 3 Proteins 0.000 description 41
- 102100021572 Bcl-2-binding component 3, isoforms 1/2 Human genes 0.000 description 41
- 238000011580 nude mouse model Methods 0.000 description 37
- 230000000694 effects Effects 0.000 description 32
- 241000699660 Mus musculus Species 0.000 description 31
- 229920001184 polypeptide Polymers 0.000 description 26
- 238000002347 injection Methods 0.000 description 16
- 239000007924 injection Substances 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 16
- 239000000370 acceptor Substances 0.000 description 15
- 238000009826 distribution Methods 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 230000034994 death Effects 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 208000029742 colonic neoplasm Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 230000000452 restraining effect Effects 0.000 description 7
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 6
- 102000000844 Cell Surface Receptors Human genes 0.000 description 6
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 6
- 108010071384 Peptide T Proteins 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 5
- 108090000397 Caspase 3 Proteins 0.000 description 5
- 102100029855 Caspase-3 Human genes 0.000 description 5
- 102000004091 Caspase-8 Human genes 0.000 description 5
- 108090000538 Caspase-8 Proteins 0.000 description 5
- 102000010911 Enzyme Precursors Human genes 0.000 description 5
- 108010062466 Enzyme Precursors Proteins 0.000 description 5
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 238000003501 co-culture Methods 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 102000004039 Caspase-9 Human genes 0.000 description 4
- 108090000566 Caspase-9 Proteins 0.000 description 4
- 108700000788 Human immunodeficiency virus 1 tat peptide (47-57) Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 description 4
- 230000005775 apoptotic pathway Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 4
- 210000004882 non-tumor cell Anatomy 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000005760 tumorsuppression Effects 0.000 description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 108010077544 Chromatin Proteins 0.000 description 3
- XPJBQTCXPJNIFE-ZETCQYMHSA-N Gly-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)CN XPJBQTCXPJNIFE-ZETCQYMHSA-N 0.000 description 3
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 3
- 101710172711 Structural protein Proteins 0.000 description 3
- 101710192266 Tegument protein VP22 Proteins 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000000118 anti-neoplastic effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 210000003483 chromatin Anatomy 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 230000012202 endocytosis Effects 0.000 description 3
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 3
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 3
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 3
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 208000003747 lymphoid leukemia Diseases 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 210000000633 nuclear envelope Anatomy 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 3
- 108010011110 polyarginine Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical group C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- UCDOXFBTMLKASE-HERUPUMHSA-N Ala-Ser-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N UCDOXFBTMLKASE-HERUPUMHSA-N 0.000 description 2
- IASNWHAGGYTEKX-IUCAKERBSA-N Arg-Arg-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(O)=O IASNWHAGGYTEKX-IUCAKERBSA-N 0.000 description 2
- LBOVBQONZJRWPV-YUMQZZPRSA-N Asp-Lys-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O LBOVBQONZJRWPV-YUMQZZPRSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PROLDOGUBQJNPG-RWMBFGLXSA-N His-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC2=CN=CN2)N)C(=O)O PROLDOGUBQJNPG-RWMBFGLXSA-N 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 238000011794 NU/NU nude mouse Methods 0.000 description 2
- 241000244206 Nematoda Species 0.000 description 2
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 2
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 101150042537 dld1 gene Proteins 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000012921 fluorescence analysis Methods 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- IKEOZQLIVHGQLJ-UHFFFAOYSA-M mitoTracker Red Chemical compound [Cl-].C1=CC(CCl)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 IKEOZQLIVHGQLJ-UHFFFAOYSA-M 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 108010029384 tryptophyl-histidine Proteins 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- RAVVEEJGALCVIN-AGVBWZICSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-5-(diamino Chemical group NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 RAVVEEJGALCVIN-AGVBWZICSA-N 0.000 description 1
- WXERCAHAIKMTKX-ZLUOBGJFSA-N Ala-Asp-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O WXERCAHAIKMTKX-ZLUOBGJFSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- OVQJAKFLFTZDNC-GUBZILKMSA-N Arg-Pro-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O OVQJAKFLFTZDNC-GUBZILKMSA-N 0.000 description 1
- 102000003916 Arrestin Human genes 0.000 description 1
- 108090000328 Arrestin Proteins 0.000 description 1
- 108010079882 Bax protein (53-86) Proteins 0.000 description 1
- 102000051485 Bcl-2 family Human genes 0.000 description 1
- 108700038897 Bcl-2 family Proteins 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000008238 LHRH Receptors Human genes 0.000 description 1
- 108010021290 LHRH Receptors Proteins 0.000 description 1
- WUFYAPWIHCUMLL-CIUDSAMLSA-N Leu-Asn-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O WUFYAPWIHCUMLL-CIUDSAMLSA-N 0.000 description 1
- OXRLYTYUXAQTHP-YUMQZZPRSA-N Leu-Gly-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(O)=O OXRLYTYUXAQTHP-YUMQZZPRSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- XTWXRUWACCXBMU-XIRDDKMYSA-N Ser-Trp-His Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CN=CN3)C(=O)O)NC(=O)[C@H](CO)N XTWXRUWACCXBMU-XIRDDKMYSA-N 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 108010044940 alanylglutamine Proteins 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 108010001064 glycyl-glycyl-glycyl-glycine Proteins 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000006667 mitochondrial pathway Effects 0.000 description 1
- 230000030544 mitochondrion distribution Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 231100001143 noxa Toxicity 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000026447 protein localization Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000003868 tissue accumulation Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 description 1
- 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200810097542 CN101580548B (zh) | 2008-05-12 | 2008-05-12 | 抑制肿瘤生长的融合肽及其在制备抗肿瘤药物中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200810097542 CN101580548B (zh) | 2008-05-12 | 2008-05-12 | 抑制肿瘤生长的融合肽及其在制备抗肿瘤药物中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101580548A CN101580548A (zh) | 2009-11-18 |
CN101580548B true CN101580548B (zh) | 2013-06-05 |
Family
ID=41362879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200810097542 Expired - Fee Related CN101580548B (zh) | 2008-05-12 | 2008-05-12 | 抑制肿瘤生长的融合肽及其在制备抗肿瘤药物中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101580548B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104356239A (zh) * | 2014-08-20 | 2015-02-18 | 华东理工大学 | 一种TAT-BH3-NΔ19 RhoGDI2融合蛋白及其制备方法和应用 |
CN110760478A (zh) * | 2018-07-27 | 2020-02-07 | 复旦大学 | 一种抗肿瘤巨噬细胞生物反应器系统及其制备方法 |
CN111793138B (zh) * | 2020-06-28 | 2021-08-17 | 江苏医药职业学院 | 一种靶向乳腺癌的融合肽及应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006029078A2 (en) * | 2004-09-07 | 2006-03-16 | The Regents Of The University Of California | Targeting transducible molecules to specific cell types |
WO2006056370A1 (en) * | 2004-11-29 | 2006-06-01 | Xigen S.A. | Fusion protein comprising a bh3-domain of a bh3-only protein |
-
2008
- 2008-05-12 CN CN 200810097542 patent/CN101580548B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006029078A2 (en) * | 2004-09-07 | 2006-03-16 | The Regents Of The University Of California | Targeting transducible molecules to specific cell types |
WO2006056370A1 (en) * | 2004-11-29 | 2006-06-01 | Xigen S.A. | Fusion protein comprising a bh3-domain of a bh3-only protein |
Non-Patent Citations (3)
Title |
---|
Eric L. Snyder et.al.Enhanced Targeting and Killing of Tumor Cells Expressing the CXC Chemokine Receptor 4 by Transducible Anticancer Peptides.《CANCER RESEARCH》.2005,第65卷10646-10650. * |
Gilbert G Prive et.al.Specific peptides for the therapeutic targeting of oncogenes.《Current Opinion in Genetics & Development》.2006,第16卷71-77. * |
Yongjun Liu et.al.BH3-based Fusion Artificial Peptide Induces Apoptosis and Targets Human Colon Cancer.《Molecular Therapy》.2009,第17卷(第9期),1509–1516. * |
Also Published As
Publication number | Publication date |
---|---|
CN101580548A (zh) | 2009-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Seidler et al. | Decorin protein core inhibits in vivo cancer growth and metabolism by hindering epidermal growth factor receptor function and triggering apoptosis via caspase-3 activation | |
CN103442705B (zh) | 用于治疗癌症和免疫抑制的昔洛舍平与线粒体抑制剂的组合 | |
CN103622915B (zh) | 一种针对脑胶质瘤的靶向纳米递药系统 | |
CN107531768A (zh) | 抗衰老化合物及其用途 | |
Ding et al. | Robust anticancer efficacy of a biologically synthesized tumor acidity-responsive and autophagy-inducing functional Beclin 1 | |
CN108047312A (zh) | 一种稳定多肽类蛋白靶向嵌合体分子及其制备方法和用途 | |
CN108570096B (zh) | 一种多肽或其衍生物及其在制备治疗肿瘤的药物中的应用 | |
ES2530091T3 (es) | Composiciones peptídicas para el tratamiento del cáncer por la inhibición de la actividad del canal de calcio TRPV6 | |
CN101580548B (zh) | 抑制肿瘤生长的融合肽及其在制备抗肿瘤药物中的用途 | |
Liu et al. | Synthesis and biological application of BKT-140 peptide modified polymer micelles for treating tumor metastasis with an enhanced cell internalization | |
Liu et al. | Biomimetic multifunctional nanodrugs enable regulating abnormal tumor metabolism and amplifying PDT-induced immunotherapy for synergistically enhanced tumor ablation | |
CN103328496A (zh) | 癌靶向肽及其于癌症治疗与诊断的应用 | |
Wang et al. | The therapeutic significance of the novel photodynamic material TPE-IQ-2O in tumors | |
Das et al. | Screening of Polymer-Based Drug Delivery Vehicles Targeting Folate Receptors in Triple-Negative Breast Cancer | |
CN107602670A (zh) | 一种可拮抗ewsr1蛋白rna结合活性的多肽eip‑22及其应用 | |
Pola et al. | Oligopeptide-targeted polymer nanoprobes for fluorescence-guided endoscopic surgery | |
Jin et al. | A tumor-specific tissue-penetrating peptide enhances the efficacy of chemotherapy drugs in gastric cancer | |
Cheung et al. | Anti-EGFR Antibody–Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth | |
Hu et al. | The antitumor effects of herbal medicine Triphala on oral cancer by inactivating PI3K/Akt signaling pathway: based on the network pharmacology, molecular docking, in vitro and in vivo experimental validation | |
Ren et al. | Non‐viral Gene Therapy for Melanoma Using Lysenin from Eisenia Foetida | |
CN111138515B (zh) | 一种靶向FGFRs的抗肿瘤小分子多肽及应用 | |
WO2017096036A1 (en) | Her2 peptide regents and methods | |
CN105859841B (zh) | 一种双靶向嵌合肽及其在制备抗肿瘤转移药物中的应用 | |
CN108586580A (zh) | 细胞穿透肽dhyhpfs及作为细胞内运送载体的用途 | |
CN109666064A (zh) | SALL4-RBBp4复合物阻断多肽和衍生抗肿瘤多肽及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: TUMOR HOSPITAL, CHINESE MEDICAL ACADEMY Free format text: FORMER OWNER: TUMOUR INST., CHINA MEDICAL SCIENCE RESEARCH ACADEMY Effective date: 20150804 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150804 Address after: 100021 Beijing, Panjiayuan, South Lane, No. 17, No. Patentee after: Tumor Hospital, Chinese Medical Academy Address before: 100021 Beijing, Panjiayuan, South Lane, No. 17, No. Patentee before: Tumour Inst., China Medical Science Research Academy |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130605 Termination date: 20180512 |
|
CF01 | Termination of patent right due to non-payment of annual fee |